ReviewFrontiers in immunology2015
Eliminating Schistosomes through Vaccination: What are the Best Immune Weapons?
Review in Frontiers in immunology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Optimization and production of a GLP-grade recombinant Sm29 vaccine against schistosomiasis: From expression to preclinical assessment.PLoS neglected tropical diseases · 2026Article
- Praziquantel resistance in schistosomes: a brief report.Frontiers in parasitology · 2024Review
- Therapeutic and vaccinomic potential of moonlighting proteins for the discovery and design of drugs and vaccines against schistosomiasis.American journal of translational research · 2024Review
- Evaluation of schistosomula lung antigen preparation and soluble egg antigen vaccines on experimental schistosomiasis mansoni.Parasites, hosts and diseases · 2023Article
- Schistosoma japonicum Tyrosine Hydroxylase is promising targets for immunodiagnosis and immunoprotection of Schistosomiasis japonica.PLoS neglected tropical diseases · 2023Article
- Pulmonary inflammation promoted by type-2 dendritic cells is a feature of human and murine schistosomiasis.Nature communications · 2023Article
- Optimization of Expression and Purification of Schistosoma mansoni Antigens in Fusion with Rhizavidin.Molecular biotechnology · 2021Article
- Evidence of Immune Modulators in the Secretome of the Equine TapewormPathogens (Basel, Switzerland) · 2021Article
- Primary and Memory Response of Human Monocytes to Vaccines: Role of Nanoparticulate Antigens in Inducing Innate Memory.Nanomaterials (Basel, Switzerland) · 2021Article
- The Genetics of Human Schistosomiasis Infection Intensity and Liver Disease: A Review.Frontiers in immunology · 2021Review
- Immunoinformatics Design of Multi-Epitope Peptide-Based Vaccine AgainstFrontiers in immunology · 2021Article
- Immunological Considerations forFrontiers in immunology · 2021Review
- Robust Immune Response Induced byInternational journal of nanomedicine · 2021Article
- Molecular Tools and Schistosomiasis Transmission Elimination.The American journal of tropical medicine and hygiene · 2020Review
- Review
- Schistosomiasis vaccine development: update on human clinical trials.Journal of biomedical science · 2020Review
- Characterization of a profilin-like protein fromPeerJ · 2020Article
- An Efficient Schistosoma japonicum Bivalent Membrane Protein Antigen DNA Vaccine Against Schistosomiasis in Mice.Medical science monitor : international medical journal of experimental and clinical research · 2019Article
- Sm16, AJournal of immunology research · 2019Article
- Schistosoma mansoni schistosomula antigens induce Th1/Pro-inflammatory cytokine responses.Parasite immunology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The successful development of vaccines depends on the knowledge of the immunological mechanisms associated with the elimination of the pathogen. In the case of schistosomes, its complex life cycle and the mechanisms developed to evade host immune system, turns the development of a vaccine against the disease into a very difficult task. Identifying the immunological effector mechanisms involved in parasite attrition and the major targets for its response is a key step to formulate an effective vaccine. Recent studies have described some promising antigens to compose a subunit vaccine and have pointed to some immune factors that play a role in parasite elimination. Here, we review the immune components and effector mechanisms associated with the protective immunity induced by those vaccine candidates and the lessons we have learned from the studies of the acquired resistance to infection in humans. We will also discuss the immune factors that correlate with protection and therefore could help to evaluate those vaccine formulations in clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.